CAS NO: | 64790-15-4 |
生物活性 | Glucagon (19-29), human is a potent and efficient inhibitor ofinsulinsecretion. | ||||||||||||||||
IC50& Target | Insulin secretion[1] | ||||||||||||||||
体外研究 (In Vitro) | Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29)[3]. | ||||||||||||||||
体内研究 (In Vivo) | Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion[1]. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+channels linked to a pathway involving a pertussis toxin-sensitive G protein[2]. | ||||||||||||||||
分子量 | 1352.53 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C61H89N15O18S | ||||||||||||||||
CAS 号 | 64790-15-4 | ||||||||||||||||
Sequence | Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr | ||||||||||||||||
Sequence Shortening | AQDFVQWLMNT | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 25 mg/mL(18.48 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |